

Dipomová práce, K. Cechová 2016: **OPRAVNÝ LÍSTEK**

Citace (str. 80-88)

- [5] M.C. Chang, S.Z. Fan, P.N. Hsiao, W.F. Cheng, W.Z. Sun, Influence of morphine on host immunity, *Acta Anaesthesiol Taiwan* 49 (2011) 105-108.
- [14] C. Borner, S. Lanciotti, T. Koch, V. Hollt, J. Kraus, mu opioid receptor agonist-selective regulation of interleukin-4 in T lymphocytes, *J Neuroimmunol* 263 (2013) 35-42.
- [20] H. Liu, H. Li, L. Guo, M. Li, C. Li, S. Wang, W. Jiang, X. Liu, M.A. McNutt, G. Li, Mechanisms involved in phosphatidylinositol 3-kinase pathway mediated up-regulation of the mu opioid receptor in lymphocytes, *Biochem Pharmacol* 79 (2010) 516-523.
- [24] C. Borner, J. Kraus, Inhibition of NF-kappaB by opioids in T cells, *J Immunol* 191 (2013) 4640-4647.
- [25] J. Gabrilovac, B. Cupic, E. Zapletal, A. Brozovic, IFN-gamma up-regulates kappa opioid receptors (KOR) on murine macrophage cell line J774, *J Neuroimmunol* 245 (2012) 56-65.
- [33] R.E. Mebius, G. Kraal, Structure and function of the spleen, *Nat Rev Immunol* 5 (2005) 606-616.
- [34] J.G. Cyster, C.C. Goodnow, Pertussis toxin inhibits migration of B and T lymphocytes into splenic white pulp cords, *J Exp Med* 182 (1995) 581-586.
- [36] J.A. Stenken, A.J. Poschenrieder, Bioanalytical chemistry of cytokines--a review, *Anal Chim Acta* 853 (2015) 95-115.
- [42] S. Roy, J. Ninkovic, S. Banerjee, R.G. Charboneau, S. Das, R. Dutta, V.A. Kirchner, L. Koodie, J. Ma, J. Meng, R.A. Barke, Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections, *J Neuroimmune Pharmacol* 6 (2011) 442-465.
- [43] J.B. Black, R.T. Premont, Y. Daaka, Feedback regulation of G protein-coupled receptor signaling by GRKs and arrestins, *Semin Cell Dev Biol* 50 (2016) 95-104.
- [48] A.S. Pupo, D.A. Duarte, V. Lima, L.B. Teixeira, E.S.L.T. Parreiras, C.M. Costa-Neto, Recent updates on GPCR biased agonism, *Pharmacol Res.* (2016)
- [55] A. Bock, N. Merten, R. Schrage, C. Dallanoce, J. Batz, J. Klockner, J. Schmitz, C. Matera, K. Simon, A. Kebig, L. Peters, A. Muller, J. Schrobang-Ley, C. Trankle, C. Hoffmann, M. De Amici, U. Holzgrabe, E. Kostenis, K. Mohr, The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling, *Nat Commun* 3 (2012) 1044.
- [64] E. Reiter, S. Ahn, A.K. Shukla, R.J. Lefkowitz, Molecular mechanism of beta-arrestin-biased agonism at seven-transmembrane receptors, *Annu Rev Pharmacol Toxicol* 52 179-197.
- [65] J.Y. Park, S.Y. Lee, H.R. Kim, M.D. Seo, K.Y. Chung, Structural mechanism of GPCR-arrestin interaction: recent breakthroughs, *Arch Pharm Res* 39 (2016) 293-301.
- [70] Z. Liu, Y. Jiang, Y. Li, J. Wang, L. Fan, M.J. Scott, G. Xiao, S. Li, T.R. Billiar, M.A. Wilson, J. Fan, TLR4 Signaling augments monocyte chemotaxis by regulating G protein-coupled receptor kinase 2 translocation, *J Immunol* 191 (2013) 857-864.
- [85] H. Ujcikova, K. Dlouha, L. Roubalova, M. Vosahlikova, D. Kagan, P. Svoboda, Up-regulation of adenylylcyclases I and II induced by long-term adaptation of rats to morphine fades away 20 days after morphine withdrawal, *Biochim Biophys Acta* 1810 (2011) 1220-1229.
- [87] N. Frolich, C. Dees, C. Paetz, X. Ren, M.J. Lohse, V.O. Nikolaev, M.H. Zenk, Distinct pharmacological properties of morphine metabolites at G(i)-protein and beta-arrestin signaling pathways activated by the human mu-opioid receptor, *Biochem Pharmacol* 81 (2011) 1248-1254.
- [88] J. McPherson, G. Rivero, M. Baptist, J. Llorente, S. Al-Sabah, C. Krasel, W.L. Dewey, C.P. Bailey, E.M. Rosethorne, S.J. Charlton, G. Henderson, E. Kelly, mu-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization, *Mol Pharmacol* 78 (2010) 756-766.

- [89] P. Molinari, V. Vezzi, M. Sbraccia, C. Gro, D. Riitano, C. Ambrosio, I. Casella, T. Costa, Morphine-like opiates selectively antagonize receptor-arrestin interactions, *J Biol Chem* 285 (2010) 12522-12535.
- [91] J.T. Williams, S.L. Ingram, G. Henderson, C. Chavkin, M. von Zastrow, S. Schulz, T. Koch, C.J. Evans, M.J. Christie, Regulation of mu-opioid receptors: desensitization, phosphorylation, internalization, and tolerance, *Pharmacol Rev* 65 (2013) 223-254.
- [95] Y. Feng, X. He, Y. Yang, D. Chao, L.H. Lazarus, Y. Xia, Current research on opioid receptor function, *Curr Drug Targets* 13 (2012) 230-246.
- [96] M. Busch-Dienstfertig, C. Stein, Opioid receptors and opioid peptide-producing leukocytes in inflammatory pain--basic and therapeutic aspects, *Brain Behav Immun* 24 (2010) 683-694.
- [97] A. Gupta, J. Mulder, I. Gomes, R. Rozenfeld, I. Bushlin, E. Ong, M. Lim, E. Maillet, M. Junek, C.M. Cahill, T. Harkany, L.A. Devi, Increased abundance of opioid receptor heteromers after chronic morphine administration, *Sci Signal* 3 (2010) ra54.
- [98] Y. Shang, M. Filizola, Opioid receptors: Structural and mechanistic insights into pharmacology and signaling, *Eur J Pharmacol* 763 (2015) 206-213.
- [107] A. Odunayo, J.R. Dodam, M.E. Kerl, A.E. DeClue, Immunomodulatory effects of opioids, *J Vet Emerg Crit Care (San Antonio)* 20 (2010) 376-385.
- [108] L. Zhang, J.S. Belkowski, T. Briscoe, T.J. Rogers, Regulation of mu opioid receptor expression in developing T cells, *J Neuroimmune Pharmacol* 7 (2012) 835-842.
- [117] S.V. Gein, Dynorphins in regulation of immune system functions, *Biochemistry (Mosc)* 79 (2014) 397-405.
- [123] S. Kasai, H. Yamamoto, E. Kamegaya, G.R. Uhl, I. Sora, M. Watanabe, K. Ikeda, Quantitative Detection of micro Opioid Receptor: Western Blot Analyses Using micro Opioid Receptor Knockout Mice, *Curr Neuropharmacol* 9 (2011) 219-222.
- [127] C. Hawrylowitz, Activation and proliferation signals in mouse B cells, *Immunology*, vol. 53, (1984) 703-711.
- [140] H. Feng, L. Guo, Z. Song, H. Gao, D. Wang, W. Fu, J. Han, Z. Li, B. Huang, X.A. Li, Caveolin-1 protects against sepsis by modulating inflammatory response, alleviating bacterial burden, and suppressing thymocyte apoptosis, *J Biol Chem* 285 (2010) 25154-25160.
- [141] S. Lin, X.M. Wang, P.E. Nadeau, A. Mergia, HIV infection upregulates caveolin 1 expression to restrict virus production, *J Virol* 84 (2010) 9487-9496.
- [147] X. Li, X. Gu, T.M. Boyce, M. Zheng, A.M. Reagan, H. Qi, N. Mandal, A.W. Cohen, M.C. Callegan, D.J. Carr, M.H. Elliott, Caveolin-1 increases proinflammatory chemoattractants and blood-retinal barrier breakdown but decreases leukocyte recruitment in inflammation, *Invest Ophthalmol Vis Sci* 55 (2014) 6224-6234.
- [151] C. Tran, C.M. Stary, J.M. Schilling, B. Bentley, H.H. Patel, D.M. Roth, Role of caveolin-3 in lymphocyte activation, *Life Sci* 121 (2015) 35-39.
- [152] P. Kirchner, M. Bug, H. Meyer, Ubiquitination of the N-terminal region of caveolin-1 regulates endosomal sorting by the VCP/p97 AAA-ATPase, *J Biol Chem* 288 (2013) 7363-7372.
- [159] J.J. Lackman, P.M. Markkanen, M. Hogue, M. Bouvier, U.E. Petaja-Repo, N-Glycan-dependent and -independent quality control of human delta opioid receptor N-terminal variants, *J Biol Chem* 289 (2014) 17830-17842.
- [163] P. Sobanski, M. Krajnik, M. Shaqura, E. Bloch-Boguslawska, M. Schafer, S.A. Mousa, The presence of mu-, delta-, and kappa-opioid receptors in human heart tissue, *Heart Vessels* 29 (2014) 855-863.
- [164] K. Tanaka, J.R. Kersten, M.L. Riess, Opioid-induced cardioprotection, *Curr Pharm Des* 20 (2014) 5696-5705.
- [165] S. Treskatsch, A. Feldheiser, M. Shaqura, L. Dehe, H. Habazettl, T.K. Ropke, M. Shakibaei, M. Schafer, C.D. Spies, S.A. Mousa, Cellular localization and adaptive changes of the cardiac delta opioid receptor system in an experimental model of heart failure in rats, *Heart Vessels* 31 (2015) 241-250.

- [169] D.K. Sarkar, A. Sengupta, C. Zhang, N. Boyadjieva, S. Murugan, Opiate antagonist prevents mu- and delta-opiate receptor dimerization to facilitate ability of agonist to control ethanol-altered natural killer cell functions and mammary tumor growth, J Biol Chem 287 (2012) 16734-16747.

Významnot rozdílů – Studentov T-test interval spolehlivosti 95%

P < 0,05 „statisticky významný rozdíl“ - (*)

P < 0,01 „statisticky vysoce významný rozdíl“ - (**)

P < 0,001 „statisticky velmi vysoce významný rozdíl“ - (***)